VMTHF OTC
Venus Medtech (Hangzhou), Inc. Class H
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +57.4%
1Y: -18.8%
3Y: -74.6%
$0.42
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$471M
-4.2% ▼
5Y CAGR: +15.1%
Gross Profit
$368M
-5.5% ▼
5Y CAGR: +13.6%
Operating Income
-$347M
+41.3% ▲
Net Income
-$714M
-1.5% ▼
EPS (Diluted)
$-1.63
-1.2% ▼
EBITDA
-$613M
-11.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $276M | $416M | $406M | $491M | $471M |
| YoY Growth | +18.3% | +50.6% | -2.3% | +20.9% | -4.2% |
| Cost of Revenue | $49M | $92M | $92M | $102M | $103M |
| Gross Profit | $227M | $324M | $314M | $389M | $368M |
| Gross Margin | 82.3% | 78.0% | 77.3% | 79.2% | 78.1% |
| R&D Expenses | $167M | $258M | $527M | $525M | $341M |
| SG&A Expenses | $239M | $345M | $453M | $454M | $391M |
| Operating Expenses | $406M | $596M | $949M | $978M | $714M |
| Operating Income | -$179M | -$279M | -$650M | -$590M | -$347M |
| Operating Margin | -64.7% | -67.0% | -160.0% | -120.1% | -73.6% |
| Interest Expense | $2M | $2M | $45M | $63M | $17M |
| Income Before Tax | -$186M | -$378M | -$1.2B | -$735M | -$741M |
| Tax Expense | -$3M | -$6M | -$34M | -$6M | -$23M |
| Net Income | -$182M | -$374M | -$1.1B | -$704M | -$714M |
| Net Margin | -65.9% | -89.8% | -260.2% | -143.2% | -151.7% |
| EPS (Diluted) | $-0.44 | $-0.85 | $-2.42 | $-1.61 | $-1.63 |
| EBITDA | -$146M | -$324M | -$999M | -$548M | -$613M |
| Shares Outstanding | 409M | 439M | 438M | 438M | 438M |